The post RVV token steady as on-chain data disputes 5.354B claim appeared on BitcoinEthereumNews.com. Did 53.54% of RVV move? Verified data says no A viral claimThe post RVV token steady as on-chain data disputes 5.354B claim appeared on BitcoinEthereumNews.com. Did 53.54% of RVV move? Verified data says no A viral claim

RVV token steady as on-chain data disputes 5.354B claim

Did 53.54% of RVV move? Verified data says no

A viral claim states the Astra project address moved 5.354 billion RVV in four days, equal to 53.54% of supply. Verifiable on-chain evidence does not support that figure.

According to EmberCN, about 860 million RVV (≈8.6% of supply) exited the minting contract and were sold for roughly 10.288 million USDT, with 8.226 million sent to exchanges and 2.041 million retained on-chain.

Based on data from Followin.io, a multi-signature wallet moved 800 million RVV into eight multi-sig wallets pre-listing. Those wallets distributed to new addresses that sold in batches, raising about $9.09 million, with at least $6.18 million consolidated by two addresses.

Why this claim matters for Astra Nova and holders

Inflated figures can misstate treasury exposure, unlock dynamics, and market integrity, creating unnecessary panic. Accurate measurements anchor risk assessments and align with compliance-focused, evidence-led reporting.

As reported by The Block, astra nova attributed the sales to a compromised third-party market maker account and pledged to buy back the affected tokens while offering a 10% bounty contingent on full return.

Astra Nova said, “a third-party market maker account was compromised.”

According to Blockchain.news, sellers converted RVV to USDT and routed sizable portions to centralized exchanges, including Gate and KuCoin, while leaving residual balances in a monitored wallet.

Price action reflected stress. As reported by the same outlet, RVV experienced a sharp decline following the concentrated on-chain sales and exchange deposits.

Concentration of sell pressure from newly funded addresses and rapid routing to exchanges are consistent with short-term liquidity shocks. These signals typically precede increased volatility and wider bid-ask spreads.

How to verify RVV transfers and flows yourself

Analyst-cited wallets, contracts, and transfer paths

Start at the RVV token’s minting contract and recent transfers. Map movements from multi-signature senders to newly created wallets, then trace batch sales and stablecoin conversions over the same time window.

Check for clustering patterns across recipient wallets and time-bound bursts. Cross-reference the amounts and paths summarized above to reconcile totals near the 800–860 million RVV range.

CEX routing noted: Gate and KuCoin deposits

Follow the USDT legs after swap events and identify exchange deposit tags. Verification should focus on routes to Gate and KuCoin that appear in the transaction paths described earlier.

FAQ about RVV token

How much RVV was actually transferred and from which wallets or contracts?

Approximately 800–860 million RVV, from a minting contract outflow and a multi-signature cluster, not 5.354 billion.

What evidence supports the claim that a market maker account was compromised?

Astra Nova’s public statement and a buyback plus 10% bounty offer, contingent on full return, were reported by a major industry publication.

Source: https://coincu.com/news/rvv-token-steady-as-on-chain-data-disputes-5-354b-claim/

Market Opportunity
Astra Nova Logo
Astra Nova Price(RVV)
$0.0005
$0.0005$0.0005
-60.15%
USD
Astra Nova (RVV) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26